Table 4.

Selected Ongoing Trials in HCM

StudyMedicationSample SizePrimary End Point
HALT-HCMNAC42Feasibility/LVM
LIBERTY-HCMGS-6615160VO2 max
INHERITLosartan130LVM
NCT01150461Losartan20LVM
NCT00319982Diltiazem39Diastolic function
METAL-HCMPerhexiline44VO2 max
NCT00011076Pirfenidne50Diastolic function
RHYMERanolazine14Safety
NCT00001534Enalapril112Symptoms
NCT00001965Cyclosporine32Safety
VANISHValsartan150Combined end point
NCT01696370Trimetazidine90VO2 max
Light-CARMIDOBX1514M406 MWT
  • HCM indicates hypertrophic cardiomyopathy; and MWT, minute walk time.